Tuesday 23 April 2024
Internal Reference Number: FOI_6396
Date Request Received: 10/12/2021 00:00:00
Date Request Replied To: 04/01/2022 00:00:00
This response was sent via: By Email
Request Summary: Treatment of Ovarian cancer
Request Category: Companies
| Question Number 1: How many patients have been treated for advanced (FIGO Stages III and IV) high-grade ovarian (epithelial ovarian, fallopian tube or primary peritoneal) cancer over the last 3 months? If none, do you refer ovarian cancer patients to another trust, if so which one? | |
| Answer To Question 1: 4 patients | |
| Question Number 2: How many ovarian cancer patients (any stage) have been treated in the last 3 months with: • Paclitaxel in combination with a platinum-based compound • Platinum-based therapy alone (cisplatin or carboplatin) • Bevacizumab in combination with paclitaxel and carboplatin • Olaparib • Olaparib + Bevacizumab • Niraparib • Rucaparib | |
| Answer To Question 2: • Paclitaxel with platinum 9 • Platinum alone 7 • Bevacizumab with paclitaxel/carboplatin 5 • Olaparib 0 • Olaparib+ bev 0 • Niraparib 5 • Rucaparib 1 | |
| Question Number 3: Of the ovarian cancer patients (any stage) treated over the last 3 months, how many patients: • Received HRD (homologous recombination deficiency) testing • Received BRCA testing • Tested HRD positive • Tested BRCA positive (BRCAm) | |
| Answer To Question 3: • Received HRD testing: 8 • Received BRCA testing: 19 • Tested HRD positive: 0 • Tested BRCA positive: 1 | |
| Question Number 4: If data for HRD testing is available, please provide how many HRD positive patients were treated in the last 3 months with: • Olaparib • Olaparib + Bevacizumab • Niraparib • Other treatments | |
| Answer To Question 4: 0 | |
| Question Number 5: If data for HRD and BRCA testing is available, please provide how many HRD positive-BRCA positive patients were treated in the last 3 months with: • Olaparib • Olaparib + Bevacizumab • Niraparib • Other treatments | |
| Answer To Question 5: • 1 patient – ‘other treatment’ treated with carboplatin/paclitaxel | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
